HemoGenyx Pharmaceuticals

Hemogenyx Pharmaceuticals plc is a pre-clinical stage biopharmaceutical company and group that is developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients who are suffering from otherwise incurable life-threatening diseases.

The Company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. HemoGenyx Pharmaceuticals focuses on bringing its cell therapy and immunotherapies to the patients who are in need.

The technology of Hemogenyx Pharmaceuticals has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

Hemogenyx Pharmaceuticals is headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, situated at its research facility in New York City and a Belgian subsidiary, Hemogenyx-Cell SPRL, located in Liège.